ExeVir Bio Looks To Llamas To Tackle Coronavirus Crisis
Raises €23m From Belgium-Based Backers
UCB and Fund+ are supporting a spin out from the renowned VIB research institute and ExeVir Bio CEO Torsten Mummenbrauer told Scrip that the firm's llama antibodies should be in the clinic for COVID-19 possibly by November.
You may also be interested in...
A Netherlands start-up Vico Therapeutics could start clinical trials in late 2021 with its antisense approach to the treatment of rare neurological diseases, financed by its large Series A.
The coronavirus research field may be dominated by vaccines from the likes of Oxford University/AstraZeneca and Pfizer/BioNTech, but a lot of interesting work is being done elsewhere by smaller academic and commercial projects looking at the potential of various novel antibody therapies against COVID-19.
Cablivi is first therapeutic to receive positive CHMP opinion for treating acquired thrombotic thrombocytopenic purpura, a rare blood disorder.